نتائج البحث - "MTOR Inhibitors"

المصدر: Oncotarget
Oncotarget, vol 7, iss 17
Liu, X; Kambrick, S; Fu, S; Naing, A; Subbiah, V; Blumenschein, GR; et al.(2016). Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. ONCOTARGET, 7(17), 23227-23238. doi: 10.18632/oncotarget.7594. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/3xx7q8fsTest

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Maximum Tolerated Dose, Bevacizumab, Oncology and Carcinogenesis, Cetuximab, and over, bevacizumab, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Internal medicine, temsirolimus, Antineoplastic Combined Chemotherapy Protocols, 80 and over, medicine, Humans, PI3K/AKT/mTOR pathway, Aged, Aged, 80 and over, Sirolimus, Hematology, business.industry, Cancer, solid tumors, Middle Aged, Prognosis, medicine.disease, Discovery and development of mTOR inhibitors, Temsirolimus, Surgery, Survival Rate, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, business, Hypophosphatemia, Research Paper, Follow-Up Studies, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a46d89e727927f9fdb71c1ce8e76522Test
https://doi.org/10.18632/oncotarget.7594Test

8

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)

المؤلفون: J. W. de Fijter, M. Reinwald, Nicolas J. Mueller, Paolo Grossi, Mario Fernández-Ruiz, José Tiago Silva, J. Fortún, Christian Garzoni, José María Aguado

المساهمون: University of Zurich, Reinwald, M

المصدر: Clinical Microbiology and Infection, 24, S53-S70
Clinical Microbiology and Infection

مصطلحات موضوعية: Microbiology (medical), mTOR inhibitors, 610 Medicine & health, Communicable Diseases, 2726 Microbiology (medical), 10234 Clinic for Infectious Diseases, Idelalisib, Immunocompromised Host, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, BCR-ABL kinase inhibitors, Humans, Medicine, Bruton's tyrosine kinase, 030212 general & internal medicine, Protein Kinase Inhibitors, Clinical Trials as Topic, Janus kinase inhibitors, biology, business.industry, Venetoclax, TOR Serine-Threonine Kinases, Ibrutinib, Cancer, 2725 Infectious Diseases, General Medicine, Protein-Tyrosine Kinases, medicine.disease, Small-molecule inhibitors, Biological Therapy, Dasatinib, Infectious Diseases, chemistry, 030220 oncology & carcinogenesis, Immunology, biology.protein, Janus kinase, business, Infection, Tyrosine kinase, Signal Transduction, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::448f16e47368750357811b7ea91f6617Test
http://hdl.handle.net/1887/86607Test

9

Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives

المؤلفون: Sara Cingarlini, Francesco Massari, Silvia Ortolani, Giampaolo Tortora, Chiara Ciccarese

المصدر: Future Oncology. 11:1809-1828

مصطلحات موضوعية: Oncology, mTOR inhibitors, renal cell carcinoma, Cancer Research, medicine.medical_specialty, Antineoplastic Agents, mTORC1, Mechanistic Target of Rapamycin Complex 1, Neuroendocrine tumors, urologic and male genital diseases, medicine.disease_cause, everolimus, mTOR pathway, neuroendocrine neoplasm, temsirolimus, Animals, Carcinoma, Renal Cell, Clinical Trials as Topic, Humans, Kidney Neoplasms, Molecular Targeted Therapy, Multiprotein Complexes, Neuroendocrine Tumors, Signal Transduction, TOR Serine-Threonine Kinases, Renal cell carcinoma, Internal medicine, medicine, PI3K/AKT/mTOR pathway, Everolimus, business.industry, Carcinoma, Renal Cell, Cancer, General Medicine, medicine.disease, Temsirolimus, Carcinogenesis, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b67969dd2b52aa6ee442bc32e5d75ec5Test
https://doi.org/10.2217/fon.15.81Test

10

Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma

المؤلفون: Katriina Peltola, Juhana Rautiola, Petri Bono, Frede Donskov, Patrick Penttilä, M. Laukka

المساهمون: Clinicum, Department of Oncology, University of Helsinki, Heikki Joensuu / Principal Investigator, HUS Comprehensive Cancer Center

المصدر: Penttilä, P, Donskov, F, Rautiola, J, Peltola, K, Laukka, M & Bono, P 2017, ' Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma ', European journal of cancer (Oxford, England : 1990), vol. 81, pp. 9-16 . https://doi.org/10.1016/j.ejca.2017.05.004Test

مصطلحات موضوعية: Male, Cancer Research, Gastroenterology, THERAPY, PULMONARY TOXICITY, 0302 clinical medicine, Renal cell carcinoma, 030212 general & internal medicine, Aged, 80 and over, MTOR INHIBITORS, Hazard ratio, mTOR-inhibitor, Middle Aged, OPEN-LABEL, CANCER, Kidney Neoplasms, 3. Good health, Oncology, 030220 oncology & carcinogenesis, Cohort, Female, medicine.drug, Adult, medicine.medical_specialty, NONINFECTIOUS PNEUMONITIS, BIOMARKERS, 3122 Cancers, Antineoplastic Agents, 03 medical and health sciences, Young Adult, Internal medicine, medicine, MANAGEMENT, Journal Article, Biomarkers, Tumor, Humans, Everolimus, Carcinoma, Renal Cell, Pneumonitis, Aged, Proportional Hazards Models, Retrospective Studies, PHASE-3 TRIAL, business.industry, Proportional hazards model, Odds ratio, Pneumonia, medicine.disease, Survival Analysis, Confidence interval, business, Tomography, X-Ray Computed, NEUROENDOCRINE TUMORS

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b68b1807c312141099bd0f9e1aa6f25bTest
https://pubmed.ncbi.nlm.nih.gov/28586749Test

تنقيح النتائج